BRAF status and mitogen-activated protein/extracellular signal regulated kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin

Ralph J. Abi-Habib, Jeffrey O. Urieto, Shihui Liu, Stephen H. Leppla, Nicholas S. Duesbery, Arthur E. Frankel

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Anthrax lethal toxin, composed of protective antigen and lethal factor, was tested for cytotoxicity to human melanoma cell lines and normal human cells. Eleven of 18 melanoma cell lines were sensitive to anthrax lethal toxin (IC50 < 400 pmol/L) and 10 of these 11 sensitive cell lines carried the V599E BRAF mutation. Most normal cell types (10 of 15) were not sensitive to anthrax lethal toxin and only 5 of 15 normal human cell types were sensitive to anthrax lethal toxin IC50 < 400 pmol/L). These cells included monocytes and a subset of endothelial cells. In both melanoma cell lines and normal cells, anthrax toxin receptor expression levels did not correlate with anthrax lethal toxin cytotoxicity. Furthermore, an anthrax toxin receptor-deficient cell line (PR230) did not show any enhanced sensitivity to anthrax lethal toxin when transfected with anthrax toxin receptor. Anthrax lethal toxin toxicity correlated with elevated phosphorylation levels of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) 1/2 in both melanoma cell lines and normal cells. Anthrax lethal toxin-sensitive melanoma cell lines and normal cells had higher phospho-MEK1/2 levels than anthrax lethal toxin-resistant melanoma cell lines and normal tissue types. UO126, a specific MEK1/2 inhibitor, was not toxic to anthrax lethal toxin-resistant melanoma cell lines but was toxic to 8 of 11 anthrax lethal toxin-sensitive cell lines. These results show that anthrax lethal toxin toxicity correlates with elevated levels of active MEK1/2 pathway but not with anthrax toxin receptor expression levels in both normal and malignant tissues. Anthrax lethal toxin may be a useful therapeutic for melanoma patients, especially those carrying the V599E BRAF mutation with constitutive activation of the mitogen-activated protein kinase pathway.

Original languageEnglish (US)
Pages (from-to)1303-1310
Number of pages8
JournalMolecular Cancer Therapeutics
Volume4
Issue number9
DOIs
StatePublished - Sep 2005

Fingerprint

Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Mitogens
Melanoma
Cell Line
Proteins
Poisons
anthrax toxin
Inhibitory Concentration 50
MAP Kinase Kinase Kinase 2
MAP Kinase Kinase Kinase 1
Mutation
Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinases
Monocytes
Endothelial Cells

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

BRAF status and mitogen-activated protein/extracellular signal regulated kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. / Abi-Habib, Ralph J.; Urieto, Jeffrey O.; Liu, Shihui; Leppla, Stephen H.; Duesbery, Nicholas S.; Frankel, Arthur E.

In: Molecular Cancer Therapeutics, Vol. 4, No. 9, 09.2005, p. 1303-1310.

Research output: Contribution to journalArticle

Abi-Habib, Ralph J. ; Urieto, Jeffrey O. ; Liu, Shihui ; Leppla, Stephen H. ; Duesbery, Nicholas S. ; Frankel, Arthur E. / BRAF status and mitogen-activated protein/extracellular signal regulated kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. In: Molecular Cancer Therapeutics. 2005 ; Vol. 4, No. 9. pp. 1303-1310.
@article{fc08ac380ff54a3a8fdfb48453c9831b,
title = "BRAF status and mitogen-activated protein/extracellular signal regulated kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin",
abstract = "Anthrax lethal toxin, composed of protective antigen and lethal factor, was tested for cytotoxicity to human melanoma cell lines and normal human cells. Eleven of 18 melanoma cell lines were sensitive to anthrax lethal toxin (IC50 < 400 pmol/L) and 10 of these 11 sensitive cell lines carried the V599E BRAF mutation. Most normal cell types (10 of 15) were not sensitive to anthrax lethal toxin and only 5 of 15 normal human cell types were sensitive to anthrax lethal toxin IC50 < 400 pmol/L). These cells included monocytes and a subset of endothelial cells. In both melanoma cell lines and normal cells, anthrax toxin receptor expression levels did not correlate with anthrax lethal toxin cytotoxicity. Furthermore, an anthrax toxin receptor-deficient cell line (PR230) did not show any enhanced sensitivity to anthrax lethal toxin when transfected with anthrax toxin receptor. Anthrax lethal toxin toxicity correlated with elevated phosphorylation levels of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) 1/2 in both melanoma cell lines and normal cells. Anthrax lethal toxin-sensitive melanoma cell lines and normal cells had higher phospho-MEK1/2 levels than anthrax lethal toxin-resistant melanoma cell lines and normal tissue types. UO126, a specific MEK1/2 inhibitor, was not toxic to anthrax lethal toxin-resistant melanoma cell lines but was toxic to 8 of 11 anthrax lethal toxin-sensitive cell lines. These results show that anthrax lethal toxin toxicity correlates with elevated levels of active MEK1/2 pathway but not with anthrax toxin receptor expression levels in both normal and malignant tissues. Anthrax lethal toxin may be a useful therapeutic for melanoma patients, especially those carrying the V599E BRAF mutation with constitutive activation of the mitogen-activated protein kinase pathway.",
author = "Abi-Habib, {Ralph J.} and Urieto, {Jeffrey O.} and Shihui Liu and Leppla, {Stephen H.} and Duesbery, {Nicholas S.} and Frankel, {Arthur E.}",
year = "2005",
month = "9",
doi = "10.1158/1535-7163.MCT-05-0145",
language = "English (US)",
volume = "4",
pages = "1303--1310",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - BRAF status and mitogen-activated protein/extracellular signal regulated kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin

AU - Abi-Habib, Ralph J.

AU - Urieto, Jeffrey O.

AU - Liu, Shihui

AU - Leppla, Stephen H.

AU - Duesbery, Nicholas S.

AU - Frankel, Arthur E.

PY - 2005/9

Y1 - 2005/9

N2 - Anthrax lethal toxin, composed of protective antigen and lethal factor, was tested for cytotoxicity to human melanoma cell lines and normal human cells. Eleven of 18 melanoma cell lines were sensitive to anthrax lethal toxin (IC50 < 400 pmol/L) and 10 of these 11 sensitive cell lines carried the V599E BRAF mutation. Most normal cell types (10 of 15) were not sensitive to anthrax lethal toxin and only 5 of 15 normal human cell types were sensitive to anthrax lethal toxin IC50 < 400 pmol/L). These cells included monocytes and a subset of endothelial cells. In both melanoma cell lines and normal cells, anthrax toxin receptor expression levels did not correlate with anthrax lethal toxin cytotoxicity. Furthermore, an anthrax toxin receptor-deficient cell line (PR230) did not show any enhanced sensitivity to anthrax lethal toxin when transfected with anthrax toxin receptor. Anthrax lethal toxin toxicity correlated with elevated phosphorylation levels of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) 1/2 in both melanoma cell lines and normal cells. Anthrax lethal toxin-sensitive melanoma cell lines and normal cells had higher phospho-MEK1/2 levels than anthrax lethal toxin-resistant melanoma cell lines and normal tissue types. UO126, a specific MEK1/2 inhibitor, was not toxic to anthrax lethal toxin-resistant melanoma cell lines but was toxic to 8 of 11 anthrax lethal toxin-sensitive cell lines. These results show that anthrax lethal toxin toxicity correlates with elevated levels of active MEK1/2 pathway but not with anthrax toxin receptor expression levels in both normal and malignant tissues. Anthrax lethal toxin may be a useful therapeutic for melanoma patients, especially those carrying the V599E BRAF mutation with constitutive activation of the mitogen-activated protein kinase pathway.

AB - Anthrax lethal toxin, composed of protective antigen and lethal factor, was tested for cytotoxicity to human melanoma cell lines and normal human cells. Eleven of 18 melanoma cell lines were sensitive to anthrax lethal toxin (IC50 < 400 pmol/L) and 10 of these 11 sensitive cell lines carried the V599E BRAF mutation. Most normal cell types (10 of 15) were not sensitive to anthrax lethal toxin and only 5 of 15 normal human cell types were sensitive to anthrax lethal toxin IC50 < 400 pmol/L). These cells included monocytes and a subset of endothelial cells. In both melanoma cell lines and normal cells, anthrax toxin receptor expression levels did not correlate with anthrax lethal toxin cytotoxicity. Furthermore, an anthrax toxin receptor-deficient cell line (PR230) did not show any enhanced sensitivity to anthrax lethal toxin when transfected with anthrax toxin receptor. Anthrax lethal toxin toxicity correlated with elevated phosphorylation levels of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) 1/2 in both melanoma cell lines and normal cells. Anthrax lethal toxin-sensitive melanoma cell lines and normal cells had higher phospho-MEK1/2 levels than anthrax lethal toxin-resistant melanoma cell lines and normal tissue types. UO126, a specific MEK1/2 inhibitor, was not toxic to anthrax lethal toxin-resistant melanoma cell lines but was toxic to 8 of 11 anthrax lethal toxin-sensitive cell lines. These results show that anthrax lethal toxin toxicity correlates with elevated levels of active MEK1/2 pathway but not with anthrax toxin receptor expression levels in both normal and malignant tissues. Anthrax lethal toxin may be a useful therapeutic for melanoma patients, especially those carrying the V599E BRAF mutation with constitutive activation of the mitogen-activated protein kinase pathway.

UR - http://www.scopus.com/inward/record.url?scp=33644690647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644690647&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0145

DO - 10.1158/1535-7163.MCT-05-0145

M3 - Article

C2 - 16170021

AN - SCOPUS:33644690647

VL - 4

SP - 1303

EP - 1310

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -